Prime Medicine, Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Prime Medicine, Inc. (PRME) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-08-06
- Prime Medicine, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-06-30 was $0.00.
- Prime Medicine, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Prime Medicine, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $0.00.
- Prime Medicine, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $0.00.
- Prime Medicine, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $83.76M, a 86.40% increase from fiscal 2024.
- Prime Medicine, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $44.94M, a 1276.26% increase from fiscal 2023.
- Prime Medicine, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $3.27M, a 88.58% decline from fiscal 2022.
- Prime Medicine, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $28.59M, a 133.12% increase from fiscal 2021.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | $0.00 derived: sum of 3 quarters · filed 2026-08-06 | $0.00 derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-05-07 | $0.00 derived: sum of 3 quarters · filed 2026-05-07 | $0.00 derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $0.00 derived: sum of 2 quarters · filed 2026-03-03 | $0.00 derived: sum of 3 quarters · filed 2026-08-06 | $83.76M 10-K · filed 2026-03-03 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $0.00 derived: sum of 2 quarters · filed 2026-08-06 | $83.76M 10-Q · filed 2025-11-07 | $83.76M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $83.76M 10-Q · filed 2026-08-06 | $83.76M derived: sum of 3 quarters · filed 2026-08-06 | $83.76M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $83.76M 10-Q · filed 2026-05-07 | $83.76M derived: sum of 2 quarters · filed 2026-05-07 | $83.76M derived: sum of 3 quarters · filed 2026-05-07 | $83.76M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $0.00 derived: sum of 2 quarters · filed 2026-03-03 | $0.00 derived: sum of 3 quarters · filed 2026-03-03 | $44.94M 10-K · filed 2026-03-03 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $0.00 derived: sum of 2 quarters · filed 2025-11-07 | $44.94M 10-Q · filed 2025-11-07 | $44.94M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $44.94M 10-Q · filed 2025-08-07 | $44.94M derived: sum of 3 quarters · filed 2025-08-07 | $44.94M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $44.94M 10-Q · filed 2025-05-08 | $44.94M derived: sum of 2 quarters · filed 2025-05-08 | $44.94M derived: sum of 3 quarters · filed 2025-05-08 | $48.20M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $0.00 derived: sum of 2 quarters · filed 2025-02-28 | $3.27M derived: sum of 3 quarters · filed 2025-02-28 | $3.27M 10-K · filed 2025-02-28 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $3.27M derived: sum of 2 quarters · filed 2024-11-12 | $3.27M 10-Q · filed 2024-11-12 | $3.27M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $3.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $3.27M 10-Q · filed 2024-08-08 | $3.27M derived: sum of 3 quarters · filed 2024-08-08 | $3.28M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-10 | $0.00 derived: sum of 2 quarters · filed 2024-05-10 | $17.00K derived: sum of 3 quarters · filed 2024-05-10 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $17.00K derived: sum of 2 quarters · filed 2024-03-01 | $28.59M 10-K · filed 2024-03-01 | |
| 2022-09-30 | $17.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $28.59M 10-Q · filed 2023-11-03 | ||
| 2022-06-30 | $28.57M 10-Q · filed 2023-08-07 | |||
| 2021-12-31 | $2.16M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $12.26M 10-K · filed 2023-03-09 | ||
| 2021-09-30 | $10.10M 10-Q · filed 2022-11-14 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |